Edesa Biotech amends CAD$23M gov't agreement, extends timeline to Dec 2028, shifts EB05 focus to general ARDS

Edesa Biotech, Inc.

Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.
First annual repayment due in 2032 (from 2029) and only if the Company earns gross revenue.
Clinical focus for EB05 changed to general ARDS from COVID-19 induced ARDS; company gains access to fully funded US government platform study.
Amendment adds reporting requirements on similar EB05 development projects and updates milestones/timelines.
Government of Canada committed up to CAD$23M ($17M USD) in partially repayable funding under original agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.